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the human papillomavirus immunisation program. The new
National Bowel Cancer Screening Program requires community
and professional education, a patient registry to ensure follow-up,
and extra resources and minimum standards to meet increased
colonoscopy demand. This will test the shared responsibilities for
health care between national and state/territory governments — a
potential barrier to efficient health policy implementation. The
community must also understand that an ineffective screening test
— one that evidence shows lacks the specificity and sensitivity to
reduce cancer mortality on a population basis — is worse than no
test at all, as the false positives and negatives can lead to poorer
health outcomes than would surveillance on a case-by-case basis.
The key is ensuring that evidence guides the implementation of
government-funded measures aimed at cancer prevention and
early detection — at a time when we could prevent well over a
third of all cancer deaths in Australia using existing prevention and
early detection technology. By investing more taxpayer funds in the
high proven returns of cancer prevention and early detection, we
could make resources available to better support the significantly
increasing numbers of new cancer patients associated with popula-
tion ageing over the coming years. Savings generated through
improved prevention could also fund targeted cancer research to
help further reduce the impact of cancer in the future. Increasing
the cancer workforce, and improving workforce training and
support through a more integrated approach across jurisdictions,
is also pivotal to ensuring we can provide optimal multidiscipli-
nary cancer care to meet the challenges of the future.
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Rheumatic fever and social justice
Alex Brown, Malcolm I McDonald and Tom Calma
High rates of this disease are the face of Indigenous disadvantage
hile acute rheumatic fever (ARF) has become a rare
curiosity in Australia’s non-Indigenous population, its
incidence in Indigenous Australians living in remote
areas remains among the highest reported in the world. It is
unlikely that such a stark contrast between two populations living
within the same national borders exists for any other disease or on
any other continent.
The new evidence-based review and guideline for diagnosis and
management of ARF and rheumatic heart disease (RHD) is an
important tool for clinicians who care for Indigenous Australians
(page 581).1 But the guideline also prescribes a clear course of
action for health policymakers. It makes a compelling case for
focusing on the provision of secondary prophylaxis via coordi-
nated, register-based RHD control programs that have guaranteed
long-term funding. At the minimum, programs are needed in the
Top End of the Northern Territory, Central Australia (including
areas of South Australia and Western Australia near the NT
border), northern WA, and northern Queensland. Other jurisdic-
tions may also require control programs, but further disease
burden data are needed to establish this.
It is critically important to ensure that people with ARF and
RHD receive good treatment and preventive care. But let’s not lose
sight of the main game. Treatment of ARF and RHD, and
secondary prevention-based control programs, are bandaid solu-
tions to an underlying tragedy.
ARF and RHD are classic diseases of social injustice. The past 50
years have witnessed dramatic declines in the prevalence of ARF
and RHD throughout the industrialised world, resulting mainly
from improvements in living conditions, socioeconomic condi-
tions, sanitation and medical care, and from reduction in house-
hold crowding.2 Unfortunately these improvements are yet to be
seen among a number of populations defined by socioeconomic
status, ethnicity or geographical location.3 In essence, ARF and
RHD are not only diseases exclusively borne by the disadvantaged,
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but also key indicators of disadvantage itself. In remote Australian
Indigenous populations, the effects of disadvantage are so
entrenched that it is likely to take several generations, and
steadfast political will, before they are overcome.
Rates of death from RHD among Aboriginal people in the Top
End of the NT exceed those reported in many industrialised
countries over a century ago.4 There is little or no evidence of
improvement over at least the past three decades.5 As a conse-
quence, Indigenous Australians continue to die before their time
from a highly preventable, highly treatable and completely avoid-
able illness.4
Ongoing disparities in the burden of ARF and RHD reflect a
number of failures in the development and delivery of health and
health-related services. Failure to provide secondary prophylaxis
can be due to missed diagnoses, poor continuity of care, a lack of
trust and communication between patients and care providers,
high staff turnover, a lack of appropriate health education, and,
perhaps most importantly, a lack of political and bureaucratic
commitment to solving the problem. Failure in primary prevention
of ARF and RHD (ie, in preventing the acquisition of group A
streptococcal infections) reflects the failure to provide Indigenous
communities with the appropriate type and level of housing and
environmental conditions that all Australians should expect.
The federal government has targeted a 50% reduction in death
due to RHD by 2008.6 While this is an unrealistic expectation,
significant achievements are possible within the short to medium
term, as has been witnessed with comprehensive approaches to
control of ARF and RHD in the French Caribbean7 and with the
establishment of register-based ARF/RHD control programs across
New Zealand.8 Perhaps the most frustrating thing is that prevent-
ing premature death due to RHD is more achievable than solving
an ever expanding list of other health and social problems facing
Indigenous Australians.
To prevent premature death due to RHD, a number of concrete
steps must be taken. Firstly, we must commit to alleviating the
underlying socioeconomic determinants of ARF and RHD. The
most important of these determinants — overcrowded housing —
is also the easiest to address, but requires a dramatically greater
investment by governments than we are currently seeing. A recent
study confirmed the extreme levels of household crowding experi-
enced in many remote communities:9 in two large NT Aboriginal
communities, the median number of people per house was 17 and
14, respectively, with a median of 6.9 and 7.5 people per bedroom,
respectively. Secondly, we must ensure that each person with a
history of ARF or RHD receives appropriate care. This entirely
achievable goal would prevent Aboriginal children dying unneces-
sarily from this disease. Thirdly, we must ensure that political will
delivers the deliverable and prevents the preventable.
As long as modern Australia continues to accept the large and
growing health and social disparities experienced by its Indigenous
people, it fails in its duty to protect and provide for the most
vulnerable. Will we be brought to account for our failure to deal
with these disparities, or will cries for justice be silenced, as has
happened with so much of the history of Australia’s first people?
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